[ Special series on Tumor angiogenesis ]

doi: 10.1186/s40880-016-0084-4

Future options of anti-angiogenic cancer therapy

Yihai Cao

Department of Microbiology, Tumor and Cell Biology, Karolinska Institute

[Abstract] In human patients, drugs that block tumor vessel growth are widely used to treat a variety of cancer types. Many rigorous phase 3 clinical trials have demonstrated significant survival benefits; however, the addition of an anti-angiogenic component to conventional therapeutic modalities has generally produced modest survival benefits for cancer patients. Currently, it is unclear why these clinically available drugs targeting the same angiogenic pathways produce dissimilar effects in preclinical models and human patients. In this article, we discuss possible mechanisms of various anti-angiogenic drugs and the future development of optimized treatment regimens.

Chinese Journal of Cancer 2016, Volume: 35, Issue 2

[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)
[Google Scholar]

[ More articles of the special series on Tumor angiogenesis ]


Cite this article

Yihai Cao. Future options of anti-angiogenic cancer therapy. Chin J Cancer. 2016, 35:21. doi:10.1186/s40880-016-0084-4


Export citations

EndNote